About the Authors

Fredrik Nyberg

Contributed equally to this work with: Fredrik Nyberg, Atsushi Ogiwara, Chris G. Harbron

Fredrik.Nyberg@astrazeneca.com

Affiliations Global Epidemiology, AstraZeneca R&D, Mölndal, Sweden, Institute of Environmental Medicine, Karolinska Institute, Stockholm, Sweden

Atsushi Ogiwara

Contributed equally to this work with: Fredrik Nyberg, Atsushi Ogiwara, Chris G. Harbron

Affiliations Research and Development Division, Medical ProteoScope Company, Tokyo, Japan, Clinical Proteome Center, Tokyo Medical University, Tokyo, Japan

Chris G. Harbron

Contributed equally to this work with: Fredrik Nyberg, Atsushi Ogiwara, Chris G. Harbron

Affiliation Discovery Statistics, AstraZeneca R&D, Macclesfield, United Kingdom

Takao Kawakami

Affiliations Research and Development Division, Medical ProteoScope Company, Tokyo, Japan, Clinical Proteome Center, Tokyo Medical University, Tokyo, Japan

Keiko Nagasaka

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Sachiko Takami

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Kazuya Wada

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Hsiao-Kun Tu

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Makiko Otsuji

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Yutaka Kyono

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Tae Dobashi

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Yasuhiko Komatsu

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Makoto Kihara

Affiliation Research and Development Division, Medical ProteoScope Company, Tokyo, Japan

Shingo Akimoto

Affiliations Research and Development Division, Medical ProteoScope Company, Tokyo, Japan, Clinical Proteome Center, Tokyo Medical University, Tokyo, Japan

Ian S. Peers

Affiliation Discovery Statistics, AstraZeneca R&D, Macclesfield, United Kingdom

Marie C. South

Affiliation Discovery Statistics, AstraZeneca R&D, Macclesfield, United Kingdom

Tim Higenbottam

Current address: Chiesi Farmaceutici, Parma, Italy

Affiliation AstraZeneca in Respiratory Biological Sciences, AstraZeneca R&D, Lund, Sweden

Masahiro Fukuoka

Affiliation Department of Medical Oncology, Kinki University School of Medicine, Osaka, Japan

Koichiro Nakata

Affiliation Nakata Clinic, Tokyo, Japan

Yuichiro Ohe

Affiliation Department of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan

Shoji Kudoh

Affiliations Japan Anti-Tuberculosis Association Fukujuji Hospital, Tokyo, Japan, Division of Pulmonary Medicine, Infectious Diseases and Oncology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

Ib Groth Clausen

Affiliation Respiratory Biological Sciences, AstraZeneca R&D, Lund, Sweden

Toshihide Nishimura

Affiliations Research and Development Division, Medical ProteoScope Company, Tokyo, Japan, Clinical Proteome Center, Tokyo Medical University, Tokyo, Japan

György Marko-Varga

Current address: Division of Clinical Protein Science and Imaging, Biomedical Center, Department of Measurement Technology and Industrial Electrical Engineering, Lund University, Lund, Sweden; Department of Surgery, Tokyo Medical University, Tokyo, Japan

Affiliations AstraZeneca in Respiratory Biological Sciences, AstraZeneca R&D, Lund, Sweden, Department of Surgery, Tokyo Medical University, Tokyo, Japan

Harubumi Kato

Affiliations Department of Surgery, Tokyo Medical University, Tokyo, Japan, Niizashiki Central General Hospital, Saitama, Japan

Competing Interests

FN, CGH, ISP, MCS and IGC are employees of AstraZeneca and own shares in the company. AO, TK, K. Nagasaka, ST, KW, HKT, MO, Y. Kyono, TD, Y. Komatsu, MK, SA, and TN are/were employees of Medical Proteoscope Co., Ltd. TH is an employee of Chiesi Farmaceutici. TH and GMV are previous employees of AstraZeneca. MF has received honoraria from AstraZeneca. K. Nakata, YO, SK, and HK have declared that no conflicts of interest exist.

Author Contributions

Conceived and designed the experiments: FN AO CGH TK Y. Kyono Y. Komatsu MK SA TH TN MF K. Nakata YO SK GMV HK. Performed the experiments: TK K. Nagasaka ST Y. Kyono TD Y. Komatsu MK. Analyzed the data: FN AO CGH TK ST KW HKT MO Y. Komatsu SA ISP MCS IGC TN GMV. Contributed reagents/materials/analysis tools: AO TK K. Nagasaka ST KW HKT MO Y. Kyono TD Y. Komatsu MK SA MF K. Nakata YO SK HK. Wrote the paper: FN AO CGH TK Y. Komatsu IGC TN GMV. Supervised clinical and epidemiological aspects of the study: FN TH MF K. Nakata YO SK HK. Supervised proteomic aspects of the study: AO TN GMV. Critical review and revision of the manuscript: FN AO CGH TK K. Nagasaka ST KW HKT MO Y. Kyono TD Y. Komatsu MK SA ISP MCS TH MF K. Nakata YO SK IGC TN GMV HK.